Medically reviewed on Jan 23, 2019
(kris a BOR ole)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Eucrisa: 2% (60 g) [contains edetate calcium disodium, propylene glycol]
Brand Names: U.S.
- Phosphodiesterase-4 Enzyme Inhibitor, Topical
- Topical Skin Product
Inhibits phosphodiesterase 4 (PDE-4) and results in increased intracellular cyclic adenosine monophosphate (cAMP) levels.
Hepatic to 2 inactive metabolites via hydrolysis and oxidation
Use: Labeled Indications
Atopic dermatitis: Topical treatment of mild to moderate atopic dermatitis in patients ≥2 years of age
Hypersensitivity to crisaborole or any component of the formulation
Atopic dermatitis: Topical: Apply a thin film to affected area(s) 2 times daily.
Refer to adult dosing.
Atopic dermatitis: Children ≥2 years and Adolescents: Topical: Apply a thin film to affected area(s) 2 times daily
For topical use only; not for ophthalmic, oral, or intravaginal use.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Riociguat: Crisaborole may enhance the hypotensive effect of Riociguat. Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension. Monitor therapy
1% to 10%: Local: Application site pain (4%)
<1%, postmarketing, and/or case reports: Hypersensitivity reaction, urticaria
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions have been reported, including contact urticaria. Severe pruritus, swelling, or erythema (at the application site or at a distant site) may be indicative of hypersensitivity. Discontinue immediately for signs of hypersensitivity.
Signs of hypersensitivity
Adverse effects were not observed in animal reproduction studies, except with high oral doses which also produced maternal toxicity.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience burning or stinging. Have patient report immediately to prescriber severe application site irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about crisaborole topical
- Crisaborole topical Side Effects
- During Pregnancy
- Dosage Information
- En Español
- 177 Reviews
- Drug class: miscellaneous topical agents
Other brands: Eucrisa